Drug Target Review Screening ebook 2021
Posted: 18 June 2021 | Drug Target Review | No comments yet
This ebook has articles on the use of screening to identify COVID-19 drugs and how assessing compound activity could accelerate drug discovery.
Screening is a vital tool in a researcher’s kit to identify new, or repurpose existing, drugs. In this ebook, learn about how screening can be applied and how challenges relating to the method can be overcome.
In this collection of articles, Dr Matthew Lloyd explains why false positive hits can arise during drug discovery and Professor Arvind Patel describes a new project at the University of Glasgow to screen for COVID-19 therapeutics. Elsewhere, discover how drugs targeting phosphodiesterase 3A to treat sarcoma were identified and why a collaboration between the Francis Crick Institute and GlaxoSmithKline for covalent fragment screening has been formed.
Included in this ebook:
- Why some screening hits are a PAIN
Dr Matthew Lloyd, University of Bath
- Assessing compound activity to accelerate drug discovery
Victoria Rees, Drug Target Review
- Screening for COVID-19 drugs
Professor Arvind Patel, University of Glasgow
- Targeting phosphodiesterase 3A: discovery of a promising cancer therapy
Dr Harri Sihto, University of Helsinki
Dr Katja Ivanitskiy and Professor Olli Kallioniemi, Sartar Therapeutics
- Covalent fragment screening in cell‑based phenotypic models of disease: a collaborative approach
Dr Andrew Powell, Dr Jacob Bush and Dr David House, GlaxoSmithKline (GSK)
Dr Katrin Rittinger and Dr Simon Boulton, The Francis Crick Institute
Assays, Drug Discovery, High-Throughput Screening (HTS), Oncology, Screening
Beckman Coulter, Horizon Discovery, Merck, X-Chem
Dr Andrew Powell (GlaxoSmithKline), Dr David House (GlaxoSmithKline), Dr Harri Sihto (University of Helsinki), Dr Jacob Bush (GlaxoSmithKline), Dr Katja Ivanitskiy (Sartar Therapeutics), Dr Katrin Rittinger (The Francis Crick Institute), Dr Simon Boulton (The Francis Crick Institute), Matthew Lloyd (University of Bath), Professor Arvind Patel (University of Glasgow), Professor Olli Kallioniemi (Sartar Therapeutics), Victoria Rees (Drug Target Review)